G & M Nicholas Pty Limited and Others v Minster for Finance and Deregulation
[2009] FCA 121
At a glance
Source factsCourt
Federal Court of Australia
Decision date
2009-02-20
Before
Cowdroy J
Source
Original judgment source is linked above.
Judgment (43 paragraphs)
REASONS FOR JUDGMENT 1 By application for an Order of Review the applicants seek to review a decision of the respondent, the Minister for Finance and Deregulation ('the Finance Minister') made on or about 21 December 2007. By his decision the Finance Minister declined to approve an act of grace payment to the applicants pursuant to s 33 of the Financial Management and Accountability Act 1997 (Cth) ('the FMA Act'). The application to this Court is made pursuant to s 39B of the Judiciary Act 1903 (Cth) and pursuant to s 5 of the Administrative Decisions (Judicial Review) Act 1977 (Cth) ('the ADJR Act').
Background 2 The second and third named applicants, Mr and Mrs Nicholas, are the directors of the first named applicant, G & M Nicholas Pty Limited which was formerly known as Medtest Pty Limited ('Medtest'). As at 2000 Medtest operated a pathology laboratory at Fairfield Heights in New South Wales ('the Medtest laboratory'). Medtest was an 'approved pathology authority' ('APA') within the meaning of s 3 of the Health Insurance Act 1973 (Cth) ('the HI Act') and the Medtest laboratory was 'an accredited pathology laboratory' ('APL') within the meaning of s 23DN of the HI Act. 3 Since the Medtest laboratory was an APL and since Medtest had provided an undertaking to the Minister for Health and Ageing ('the Minister for Health') in accordance with s 23DF of the HI Act, Medicare benefits were payable under s 16A(2) of the HI Act in respect of pathology test services provided by Medtest. 4 An approval provided under s 23DN is liable to be revoked or varied by the Minister for Health pursuant to s 23DN(6) of the HI Act. Section 23DNA allows the Minister for Health to determine the principles to be applied in the exercise of the power conferred by s 23DN. Such principles have been determined and are known as the Health Insurance (Accredited Pathology Laboratories - Approval) Principles 1999 ('the Principles'). 5 The Principles provide for the Minister for Health to evaluate an APL in accordance with the criteria established by an independent body, namely the National Association of Testing Authorities ('NATA') and for that purpose to consider reports of NATA's Medical Testing Accreditation Advisory Committee ('MTAAC'). NATA periodically conducts inspections of APLs on behalf of the Minister for Health pursuant to a Memorandum of Understanding between the Commonwealth and NATA. Such inspections determine whether APLs meet technical standards appropriate to allow approval to remain in force under s 23DN of the HI Act. 6 In August 2000 NATA conducted a periodic inspection of the Medtest laboratory and an MTAAC report was prepared regarding the inspection. Such report stated that the Medtest laboratory's rate of reporting of high-grade anomalies of gynaecological cytology specimens was less than the expected rate. In consequence NATA required Medtest to submit specimens for an independent external review conducted by the Prince of Wales Hospital. The review challenged Medtest's diagnosis in seven of 528 pap smear cases. Ultimately however Medtest's diagnosis in each of those seven cases was found to be correct. 7 In March 2001 a further inspection of the Medtest laboratory was conducted by NATA and a further MTAAC report was prepared of such inspection. The report stated that defects were found in the staffing, resources and procedures of the Medtest laboratory. Such report recommended that the accreditation of the Medtest laboratory by NATA not be renewed. 8 On the basis of such report the NATA Board resolved to cancel NATA's approval of the Medtest laboratory as an APL on 20 August 2001. However such cancellation was suspended pending an appeal by Medtest to NATA's Review Committee. 9 On 11 March 2002 the Minister for Health answered questions in a Question Time session before the Senate. In the course of answering questions the Minister for Health referred to NATA's decision relating to Medtest and the pending appeal, and quoted a passage from the MTAAC report pointing to deficiencies in the staffing, resources and procedures of the Medtest laboratory. The Minister for Health informed the Senate that she had directed the Managing Director of the Health Insurance Commission ('the HIC') to withdraw the APL status of the Medtest laboratory pending resolution of the NATA process. 10 In her response to questions in the Senate, the Minister for Health made reference to two matters of significance to these proceedings. Firstly the Minister for Health informed the Senate that she had written to the New South Wales Minister for Health ('the NSW Health Minister') advising of the concerns in relation to the Medtest laboratory. Secondly the Minister for Health informed the Senate that she had directed the Department of Health and Ageing to contact all medical practitioners who had referred patients to Medtest over the past three years and inform them of NATA's concerns. 11 By letter dated 15 March 2002, but forwarded on 18 March 2002, the Chief Medical Officer of the Department of Health and Ageing wrote, as directed by the Minister for Health, to medical practitioners who had requested pathology services from Medtest. Such letter advised those medical practitioners of NATA's concerns regarding the accuracy of test results provided by Medtest. The New South Wales Department of Health ('NSW Health') also posted a warning on its website to similar effect ('the website warning'). 12 The approval of the Medtest laboratory as an APL under s 23DN of the HI Act was due to expire on 30 April 2002. Notwithstanding the approaching expiration, on 14 March 2002 the Managing Director of the HIC acting as delegate of the Minister for Health revoked approval of the Medtest laboratory under s 23DN of the HI Act. 13 On 15 March 2002 Medtest applied to the Administrative Appeals Tribunal ('the AAT') for a review of the delegate's decision and on that day the AAT granted a stay of such decision. 14 On 16 April 2002 Medtest applied to the Minister for Health for a variation of the existing approval to extend beyond 30 April 2002 and for a grant of a new approval from 30 April 2002. Both applications were refused under s 23DN of the HI Act by a delegate of the Minister for Health. In consequence Medtest immediately applied to the AAT for a review of both decisions. The AAT granted a stay of each decision and as a result the expiration date of 30 April 2002 was treated as having been extended pending a final hearing before the AAT. 15 Thereafter Medtest applied to NATA for approval of its laboratory as an APL under s 23DN of the HI Act. In the course of the negotiations for an inspection, the date of 18 April 2002 was referred to. According to the Tribunal decision of 23 December 2003, on 15 May 2002 the Minister for Health issued Medtest a notice under s 23DL of the HI Act stating that there were reasonable grounds for believing that Medtest had refused to permit inspection on 18 April 2002 in breach of its undertaking under s 23DF of the HI Act. The Minister for Health referred the matter to the Medicare Participation Review Committee ('the MPRC'). 16 On 16 May 2002 NATA conducted a new assessment of the Medtest laboratory with the outcome being that on 27 June 2002 the applicant was granted accreditation. As at this date the existing review applications to the AAT had not been heard. 17 On 4 July 2002 the AAT heard Medtest's application for a review of the decisions made on 30 April 2002 under s 23DN of the HI Act. In consequence of NATA's recent decision to re-accredit Medtest, the Minister for Health accepted before the AAT that the decision refusing to approve the renewal of the APL status should be set aside and that the AAT should substitute a new decision approving the laboratory as an APL. 18 The only remaining issue concerned the length of time of re-accreditation. The re-accreditation provided by NATA following its decision in June 2002 was for a period of three years conditional upon a reassessment being conducted between six and 12 months after the date of re-accreditation. 19 On 10 July 2002 the AAT granted a 12 month period of re-accreditation. The Tribunal observed at [38] of its decision: None of the evidence before the Tribunal indicates that public health and safety have been jeopardised, and the Respondent did not contend this.